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Conclusions: 3D image-guided BT allows accurate 
identification of uterine perforations, preventing potential 
acute and long term complications, while ensuring that the 
appropriated dose is delivered to the target volume. 
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Purpose/Objective: Compare the dosimetry for plans 
generated by using the GEC –ESTRO guidelines with a 
traditional point A prescription in terms of tumourcoverage 
and dose to the OARs. 
Materials and Methods: The plans of 30 patients with 
cervical cancerwere reviewed, they all received EBRT to 
45Gy in 25 fractions with concurrentcisplatin chemotherapy. 
They had 3 CT guided individualised fractions of HDR 
brachytherapyaiming for a d90 >80Gy whilst respecting the 
published OARs dose constraints.These were compared with 
plans generated using the 3 CT plans for each patientto 
deliver a prescription of 7Gy to point A. The plans were 
compared in termsof the d90 to the HRCTV, v100 receiving 7 
Gy/ fraction, and the 2cc doses tobladder, rectum, sigmoid, 
small bowel and GI total. We also compared the d90per cm3 
of HRCTV as a surrogate of treatment delivery efficiency. 
Thepaired t-test (T) and pearson correlation coefficient (r) 
were used with2-tailed significance testing level of 0.05. 
Results: A total of 90 individualised plans were compared 
with 90 plans using point A prescription. The median HRCTV 
volume was 30.7cm3(20.1 – 72.4cm3), the total combined 
doses to point A for eachtechnique were comparable with a 
median dose of 75Gy for individualised planning and 73.6Gy 
for plans prescribed to point A. Descriptive data 
comparingthe 2 plans is in table 1: 
 
 
There was a statistically significant difference in the d90 
doses achieved by individualised planning compared to 
prescribing to point A,also only 4 (13%) cases using IGBTfailed 
to achieve a dose of >80Gy compared to 19 cases (63%). 
Although the median doses to the OARs were higher for 
individualised plans, this is contrasted by the number of 
cases who would have received clinically significant doses 
above the accepted dose constraints when prescribing to 
point A, where 2 cases would have received doses of 88.4 Gy 
and 90.9 Gy to the small bowel for a non-individualised plan. 
When looking at the impact of the HRCTV volume on the dose 
delivered to the tumour there was a negative correlation for 
both techniques. There was a stronger association for point A 
prescribing(r=-0.87; p<0.0001) compared to individualised 
planning (r=-0.52;p<0.003). Conforming the dose to the 
tumour volume and shape appears to mitigate for the 
negative effect of large HRCTV volumes. 
Conclusions: Individualised treatment planning for each 
brachytherapyfraction using CT scans allows an increase in 
the number of patients achievinga d90 of >80Gy whilst 
staying within the OARs dose constraints. Prescribingto point 
A without conforming the dose withimage guidance can result 
in a number of patients receiving clinicallysignificant 
overdoses to the OARs with most likely serious long term 
toxicity. 
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Purpose/Objective: To assess the impact of dose constraints 
on the clinical outcome in radio(chemo)therapy and MRI 
based image-guided adaptive brachytherapy (IGABT) for 
cervical cancer. 
Materials and Methods: Our study population consists of 225 
consecutive cervical cancer patients (FIGO stages IB - IVA) 
treated between 1998 – 2008 by external beam radiotherapy 
(EBRT) +/- chemotherapy and IGABT. For this retrospective 
study patients were stratified into two treatment groups: 
Group 1 (optimal treatment): all dose constraints fulfilled. 
Group 2 (suboptimal treatment): one or more dose 
constraints not fulfilled. The following dose constraints (EBRT 
+ brachytherapy dose) were applied: CTVHR D90 ≥85 Gy, D2cc 
rectum < 70 Gy, D2cc bladder <90 Gy. All doses were 
calculated by summation of the dose of all EBRT and 
brachytherapy fractions using the EQD2 model (α/β=10 Gy for 
target volume and α/β =3 Gy for OARs). Differences in event 
free interval [local tumor control and grade 4 toxicity 
(surgery necessary) according to LENT-SOMA score] were 
compared between the two treatment groups. 
Results: Optimal treatment received 77 (34%) and suboptimal 
148 (66%) of the patients. The mean follow-up in group 1 and 
group 2 was 54 and 49 months, respectively. FIGO stage in 
group 1 versus group 2 was: stage I 14 (18%) vs. 11 (7%), p= 
0.015, stage II 49 (64%) vs. 88 (60%), p= 0.545, stage III 14 
(18%) vs. 39 (26%), p= 0.172 and stage IV 0 (0%) vs. 10 (7%), 
p=0.020. There was a significant difference in the volume of 
HRCTV between the two groups (Group 1 vs. group 2: 34.2 
cm³ vs. 47.8 cm³, p=0.001).  
Five-year local recurrence free interval was 92.8% in group 1 
and 80.8% in group 2 (p=0.028). Grade 4 rectal toxicity was 
observed in 2 cases in group 1 and 1 case in group 2. Grade 4 
bladder toxicity was observed in 0 cases in group 1 and 2 
cases in group 2. Five-year event free interval (local 
recurrence or G4 toxicity) in group 1 and 2 was 90 % and 79% 
respectively (p=0.056). 
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Conclusions: Patients treated with an optimal treatment 
plan have 10% probability of experiencing treatment failure 
in terms of local recurrence or severe treatment related 
toxicity. In patients with suboptimal treatment plans the risk 
for treatment failure doubles. More, impact of dose volume 
constraints on the clinical results suggests that the highest 
priority in treatment planning should be given to reach the 
planning aims for the target dose coverage.  
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Purpose/Objective: Treatment of locally advanced cervical 
cancer involves multidisciplinary care using external beam 
radiotherapy, chemotherapy, brachytherapy, and surgery. We 
aimed to compare both tumor and treatment characteristics 
between with patients with complete pathologic response 
(CR) and patients with residual disease (RD). 
Materials and Methods: This monocentric restrospective 
study included 40 consecutive patients, treated with external 
beam radiotherapy, pulsed-dose-rate brachytherapy and 
completion surgery. Treatment planning was performed to 
obtain a cumulative D90 value for the intermediate-risk 
clinical target volume (IR-CTV) ≥ 60α/β=10. Different clinical 
and dosimetric parameters were analyzed and compared 
between patients with RD and those with CR. 
Results: We observed 18 (45%) patients with CR and 22 (55%) 
patients with RD. In univariate analysis, patients with RD had 
a significantly longer overall treatment time than those with 
CR (59.5 vs 53 days, p = 0.0321). The D90 value for the high-
risk CTV (HR-CTV) was higher in the group with CR than in the 
group with RD (65.9 vs 64.2Gyα/β=10, p = 0.0439). In 
multivariate analysis, overall treatment time remained the 
only predictive factor for CR (p = 0.033), even if the 
difference for D90 HR-CTV kept a trend toward significance (p 
= 0.057). 
Conclusions: This study showed that tumor sterilization is 
significantly correlated with overall treatment time and 
probably with cumulative dose delivered to the HR-CTV. 
These results emphasize the attention that must be given to 
treatment organization and dosimetry optimization.  
   
 
Electronic Poster: Brachytherapy track: Physics  
 
 
EP-1603   
A scintillating fiber optic dosimeter for LDR and HDR 
brachytherapy 
L. Moutinho1, I.F.C. Castro1, J.F.C.A. Veloso1 
1I3N- Universidade de Aveiro, Physics Department, Aveiro, 
Portugal  
 
Purpose/Objective: An ideal dosimeter for prostate 
brachytherapy should present high sensitivity, no 
dependencies on beam parameters, real-time and in-vivo 
dose measurement, independence of dose rate and 
temperature, dose linearity, tissue equivalence, be easy to 
use and calibrate, detectable in the anatomic volume to 
check its position, not expensive and with disposable use of 
its implantable part.  
Organic scintillating materials have been used for radiation 
detection for decades. Despite of the low density of these 
materials, their fast response and near water equivalence 
make them suitable for in-vivo and real-time dosimetry. We 
evaluated the performance of these materials under regimes 
such as the ones found in prostate Low Dose Rate (LDR) and 
High Dose Rate (HDR) brachytherapy. 
We developed a scintillator fiber optic dosimeter in two 
configurations suitable for both LDR and HDR prostate 
brachytherapy comprising two disposable probes adapted to 
both modalities. 
LDR typically uses low energy emitters (< 50 keV) and for that 
reason a high sensitivity device is required. Our detector uses 
a 5mm scintillating fiber optic optically coupled to a fiber 
optic waveguide with a silicon photomultiplier (SiPM) for light 
readout. SiPMs are solid-state devices, comprising multiple 
pixels that behave as Geiger-mode avalanche photodiode 
detectors individually. These devices allow the development 
of lower cost dosimetric devices but because they present a 
characteristic dark noise, we developed a patented solution 
to overcome this issue. 
On the other hand, HDR uses radiation with energies above 
the Cherenkov threshold for organic materials. This means 
that a blue light is present as a form of noise when a charged 
particle travels through the medium with a velocity higher 
than the velocity of light in that material.  
Materials and Methods: The scintillating fiber optic used is a 
BCF-12 (Saint-Gobain) optically coupled to a PMMA 1 mm core 
fiber optic (Avago Techonologies). The SiPM used is a 1mm2 
Multi-Pixel Photon Counter (MPPC) from Hamamatsu. 
Results: The dosimeter shows a linear response with dose and 
is capable of detecting mGy dose variations like an ionization 
chamber. Besides fulfilling all the requirements for a 
dosimeter in brachytherapy, the high sensitivity of this 
device makes it a suitable candidate for application in LDR-
brachytherapy. Energy linearity for energies below 50 keV 
using monochromatic x-ray photons will be presented.  
Conclusions: Clinical in-vitro tests were performed in 
collaboration with two Portuguese public hospitals and 
results from both LDR and HDR studies will be presented.  
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Purpose/Objective: We intend to show technical aspects of 
the treatment of facial and thoracic skin lesions with high 
dose rate (HDR) plesiotherapy. 
Materials and Methods: Eighteen treatments in sixteen 
patients with sarcoma, basal cell and squamous cell 
carcinoma in facial region (12) and cutaneous metastasis of 
breast cancer in thoracic region (6) were performed. Facial 
